Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide. The aim of our study was to assess the role of bilirubin, and the heme oxygenase 1 (HMOX1) and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variants, which are involved in bilirubin homeostasis, in the NAFLD development in adult patients. The study was performed on 84 patients with NAFLD and 103 age/sex-matched controls. Routine biochemistry, inflammatory markers, adipokines, and the fibrosis/steatohepatitis stage were determined in the NAFLD patients. The (GT)n/(TA)n dinucleotide variations in HMOX1/UGT1A1 gene promoters, respectively, were analyzed by fragment analysis. Compared to controls, serum bilirubin concentrations in NAFLD patients tended to be decreased, while the prevalence of phenotypic Gilbert syndrome was significantly low. Genetic variations in HMOX1 and UGT1A1 gene promoters did not differ between NAFLD patients and controls, and no relationship was found in the NAFLD patients between these gene variants and any of the laboratory or histological parameters. In conclusion, metabolism of bilirubin is dysregulated in NAFLD patients, most likely due to increased oxidative stress, since frequencies of the major functional variants in the HMOX1 or UGT1A1 gene promoters did not have any effect on development of NAFLD in adult patients.

4th Department of Internal Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague 120 00 Prague Czech Republic

Institute of Clinical and Experimental Medicine 140 00 Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague 120 00 Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague 120 00 Prague Czech Republic

Zobrazit více v PubMed

Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923. doi: 10.1053/jhep.2003.50161. PubMed DOI

Chalasani N., Younossi Z., LaVine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. doi: 10.1002/hep.29367. PubMed DOI

Yilmaz Y. Review article: Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment. Pharmacol. Ther. 2012;36:815–823. doi: 10.1111/apt.12046. PubMed DOI

Day C.P., James O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114:842–845. doi: 10.1016/S0016-5085(98)70599-2. PubMed DOI

Cortez-Pinto H., de Moura M.C., Day C.P. Non-alcoholic steatohepatitis: From cell biology to clinical practice. J. Hepatol. 2006;44:197–208. doi: 10.1016/j.jhep.2005.09.002. PubMed DOI

Pessayre D., Fromenty B. NASH: A mitochondrial disease. J. Hepatol. 2005;42:928–940. doi: 10.1016/j.jhep.2005.03.004. PubMed DOI

Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 2002;37:56–62. doi: 10.1016/S0168-8278(02)00073-9. PubMed DOI

Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: A narrative re-view. Gastroenterol. Hepatol. 2012;35:32–41. doi: 10.1016/j.gastrohep.2011.08.002. PubMed DOI

Exner M., Minar E., Wagner O., Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free. Radic. Biol. Med. 2004;37:1097–1104. doi: 10.1016/j.freeradbiomed.2004.07.008. PubMed DOI

Chang P.-F., Lin Y.-C., Liu K., Yeh S.-J., Ni Y.-H. Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease. Int. J. Obes. 2015;39:1236–1240. doi: 10.1038/ijo.2015.46. PubMed DOI

Malaguarnera L., Madeddu R., Palio E., Arena N., Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J. Hepatol. 2005;42:585–591. doi: 10.1016/j.jhep.2004.11.040. PubMed DOI

Salley T.N., Mishra M., Tiwari S., Jadhav A., Ndisang J.F. The Heme Oxygenase System Rescues Hepatic Deterioration in the Condition of Obesity Co-Morbid with Type-2 Diabetes. PLoS ONE. 2013;8:e79270. doi: 10.1371/journal.pone.0079270. PubMed DOI PMC

Hinds T.D., Jr., Sodhi K., Meadows C., Fedorova L., Puri N., Kim D.H., Peterson S.J., Shapiro J.I., Abraham N.G., Kappas A. Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity. 2014;22:705–712. doi: 10.1002/oby.20559. PubMed DOI PMC

Vítek L., Schwertner H.A. The Heme Catabolic Pathway and its Protective Effects on Oxidative Stress-Mediated Diseases. Adv. Appl. Microbiol. 2007;43:1–57. doi: 10.1016/s0065-2423(06)43001-8. PubMed DOI

Vítek L., Tiribelli C. Bilirubin: The yellow hormone? J. Hepatol. 2021;75:1485–1490. doi: 10.1016/j.jhep.2021.06.010. PubMed DOI

Lin Y.-C., Chang P.-F., Hu F.-C., Chang M.-H., Ni Y.-H. Variants in the UGT1A1 gene and the risk of pediatric nonalco-holic fatty liver disease. Pediatrics. 2009;124:E1221–E1227. doi: 10.1542/peds.2008-3087. PubMed DOI

Vítek L. Bilirubin as a signaling molecule. Med. Res. Rev. 2020;40:1335–1351. doi: 10.1002/med.21660. PubMed DOI

Kwak M.-S., Kim D., Chung G.E., Kang S.J., Park M.J., Kim Y.J., Yoon J.-H., Lee H.-S. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2012;18:383–390. doi: 10.3350/cmh.2012.18.4.383. PubMed DOI PMC

Salomone F., Volti G.L., Rosso C., Grosso G., Bugianesi E. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis. J. Gastroenterol. Hepatol. 2013;28:1202–1208. doi: 10.1111/jgh.12155. PubMed DOI

Hjelkrem M., Morales A., Williams C.D., Harrison S.A. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH) Aliment. Pharmacol. Ther. 2012;35:1416–1423. doi: 10.1111/j.1365-2036.2012.05114.x. PubMed DOI

Puri K., Nobili V., Melville K., Corte C.D., Sartorelli M.R., Lopez R., Feldstein A.E., Alkhouri N. Serum Bilirubin Level Is Inversely Associated With Nonalcoholic Steatohepatitis in Children. J. Pediatr. Gastroenterol. Nutr. 2013;57:114–118. doi: 10.1097/MPG.0b013e318291fefe. PubMed DOI

Luo L., An P., Jia X., Yue X., Zheng S., Liu S., Chen Y., An W., Winkler C.A., Duan Z. Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. Front. Genet. 2018;9:662. doi: 10.3389/fgene.2018.00662. PubMed DOI PMC

Kunutsor S.K., Frysz M., Verweij N., Kieneker L.M., Bakker S.J.L., Dullaart R.P.F. Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: Observational findings and a Mendelian randomization study. Eur. J. Epidemiol. 2020;35:123–137. doi: 10.1007/s10654-019-00589-0. PubMed DOI PMC

Bellarosa C., Bedogni G., Bianco A., Cicolini S., Caroli D., Tiribelli C., Sartorio A. Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children. J. Clin. Med. 2021;10:2812. doi: 10.3390/jcm10132812. PubMed DOI PMC

Tarantino G., Colao A., Capone D., Conca P., Tarantino M., Grimaldi E., Chianese D., Finelli C., Contaldo F., Scopacasa F., et al. Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J. Boil. Regul. Homeost. Agents. 2011;25:47–56. PubMed

Chisholm J., Seki Y., Toouli J., Stahl J., Collins J., Kow L. Serologic predictors of nonalcoholic steatohepatitis in a popula-tion undergoing bariatric surgery. Surg. Obes. Relat. Dis. 2012;8:416–422. doi: 10.1016/j.soard.2011.06.010. PubMed DOI

Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Dis-eases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. doi: 10.1002/hep.25762. PubMed DOI

Jiraskova A., Lenicek M., Vitek L. Simultaneous genotyping of microsatellite variations in HMOX1 and UGT1A1 genes us-ing multicolored capillary electrophoresis. Clin. Biochem. 2010;43:697–699. doi: 10.1016/j.clinbiochem.2010.01.006. PubMed DOI

Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.-C., Torbenson M.S., Unalp-Arida A., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701. PubMed DOI

Wai C.-T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., Lok A.S.-F. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526. doi: 10.1053/jhep.2003.50346. PubMed DOI

Sterling R.K., Lissen E., Clumeck N., Sola R., Correa M.C., Montaner J., Sulkowski M.S., Torriani F.J., Dieterich D.T., Thomas D.L., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325. doi: 10.1002/hep.21178. PubMed DOI

Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., Enders F., Saksena S., Burt A.D., Bida J.P., et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854. doi: 10.1002/hep.21496. PubMed DOI

Harrison S.A., Oliver D., Arnold H.L., Gogia S., Neuschwander-Tetri B.A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–1447. doi: 10.1136/gut.2007.146019. PubMed DOI

Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin Is an Antioxidant of Possible Physiological Importance. Science. 1987;235:1043–1046. doi: 10.1126/science.3029864. PubMed DOI

Wagner K.-H., Wallner M., Moelzer C., Gazzin S., Bulmer A.C., Tiribelli C., Vitek L. Looking to the horizon: The role of bilirubin in the development and prevention of age-related chronic diseases. Clin. Sci. 2015;129:1–25. doi: 10.1042/CS20140566. PubMed DOI

Lin J.P., Vitek L., Schwertner H.A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardio-vascular disease. Clin. Chem. 2010;56:1535–1543. doi: 10.1373/clinchem.2010.151043. PubMed DOI

Urbanek P., Lenicek M., Muchova L., Subhanova I., Dusek L., Kasprikova N., Hrabal P., Bruha R., Vitek L. No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. Ann. Hepatol. 2011;10:445–451. doi: 10.1016/S1665-2681(19)31511-X. PubMed DOI

Belo L., Nascimento H., Kohlova M., Bronze-da-Rocha E., Fernandes J., Costa E., Catarino C., Aires L., Mansilha H.F., Rocha-Pereira P., et al. Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymor-phism in young obese. PLoS ONE. 2014;9:e98467. doi: 10.1371/journal.pone.0098467. PubMed DOI PMC

Vítek L. The Role of Bilirubin in Diabetes, Metabolic Syndrome, and Cardiovascular Diseases. Front. Pharmacol. 2012;3:55. doi: 10.3389/fphar.2012.00055. PubMed DOI PMC

Novotný L., Vitek L. Inverse Relationship between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies. Exp. Biol. Med. 2003;228:568–571. doi: 10.1177/15353702-0322805-29. PubMed DOI

Korkmaz H., Unler G.K., Gokturk H.S., Schmidt W.E., Kebapcilar L. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test. Eur. J. Gastroenterol. Hepatol. 2015;27:1137–1143. doi: 10.1097/MEG.0000000000000407. PubMed DOI

Eng K., Lopez R., Liccardo D., Nobili V., Alkhouri N. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Dig. Liver Dis. 2014;46:1008–1013. doi: 10.1016/j.dld.2014.07.016. PubMed DOI

Poynard T., Ratziu V., Charlotte F., Messous D., Munteanu M., Imbert-Bismut F., Massard J., Bonyhay L., Tahiri M., Thabut D., et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34. doi: 10.1186/1471-230X-6-34. PubMed DOI PMC

Demir M., Lang S., Schlattjan M., Drebber U., Wedemeyer I., Nierhoff D., Kaul I., Sowa J., Canbay A., Töx U., et al. NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD. PLoS ONE. 2013;8:e58360. doi: 10.1371/journal.pone.0058360. PubMed DOI PMC

Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., Tahiri M., Munteanu M., Thabut D., Ca-dranel J.F., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. doi: 10.1186/1471-230X-6-6. PubMed DOI PMC

Stepanova M., Aquino R., Alsheddi A., Gupta R., Fang Y., Younossi Z. Clinical predictors of fibrosis in patients with chronic liver disease. Aliment. Pharmacol. Ther. 2010;31:1085–1094. doi: 10.1111/j.1365-2036.2010.04266.x. PubMed DOI

Association of Low Serum Bilirubin Concentrations and Promoter Variations in the UGT1A1 and HMOX1 Genes with Type 2 Diabetes Mellitus in the Czech Population

Serum Bilirubin and Markers of Oxidative Stress and Inflammation in a Healthy Population and in Patients with Various Forms of Atherosclerosis